John Green, MD
Internal Medicine · Bristol, TNNPI 1740288380
Payments from drug & device makers
Across 76 payments — averaging $17.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$186
- Novo Nordisk$175
- Johnson & Johnson$131
- Calliditas Therapeutics US Inc.$99
- Pfizer$92
- Daiichi Sankyo Inc.$87
- plus $563 from 22 others
What the payments were for
- Speaking & faculty fees$453%
- Food & beverage$1,28897%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 11 | $186 |
| Novo Nordisk | 12 | $175 |
| Johnson & Johnson | 10 | $131 |
| Calliditas Therapeutics US Inc. | 4 | $99 |
| Pfizer | 4 | $92 |
| Daiichi Sankyo Inc. | 4 | $87 |
| AstraZeneca | 4 | $85 |
| Mallinckrodt Hospital Products Inc. | 2 | $41 |
| GSK | 2 | $38 |
| Inogen, Inc. | 2 | $37 |
| Eisai Inc. | 2 | $36 |
| Amgen(2 entities) | 2 | $36 |
| Acadia Pharmaceuticals Inc | 2 | $33 |
| Lundbeck LLC | 1 | $31 |
| Biogen | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Travere Therapeutics, Inc. | 1 | $20 |
| Boehringer Ingelheim | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Amarin Pharma, Inc. | 1 | $16 |
| OPKO Pharmaceuticals, LLC | 1 | $16 |
| Corium, LLC | 1 | $15 |
| AbbVie | 1 | $14 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
| Almatica Pharma LLC | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Novartis | 1 | $12 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
How this compares
$1,334 in reported general payments places this provider in the 70th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 168 | $151,171 |
| EnbrelEtanercept | 13 | $111,454 |
| XareltoRivaroxaban | 41 | $46,083 |
| FarxigaDapagliflozin Propanediol | 38 | $32,448 |
| OzempicSemaglutide | 27 | $32,196 |
| JardianceEmpagliflozin | 36 | $26,905 |
| Breo ElliptaFluticasone/Vilanterol | 23 | $16,629 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 15 | $8,896 |
| MyrbetriqMirabegron | 13 | $7,016 |
| Atorvastatin Calcium | 528 | $5,658 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 272 | $5,546 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,371 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 137 | $4,055 |
| Omeprazole | 297 | $3,465 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 123 | $3,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $92 | $151,171168 claims |
| AmgenEnbrel | $36 | $111,45413 claims |
| Johnson & JohnsonXarelto | $131 | $46,08341 claims |
| AstraZenecaFarxiga, Symbicort | $85 | $36,81953 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $18 | $35,80251 claims |
| Novo NordiskOzempic | $175 | $32,19627 claims |
| GSKBreo Ellipta | $38 | $16,62923 claims |
| Almatica Pharma LLCSertraline Hcl | $13 | $1,210160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Bristol
- Bernard GrunstraBristol$6.4M
- Rick WhilesBristol$1.5M
- Donald QuinnBristol$868K
- Stephanie PowellBristol$170K
- Shelby OldsBristol$89K
- Mark McKenzieChattanooga$11.9M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.